We conducted a survey to compare antimicrobial stewardship outcomes considered to be most important with those used in practice as metrics. Respondent opinion of important outcomes compared with those collected as metrics were antimicrobial use (15% vs 73%), antimicrobial cost (10% vs 73%), appropriateness of antimicrobial use (56% vs 51%), infection-related mortality rate (34% vs 7%), and antibiotic-associated length of stay (22% vs 12%). Patient outcomes are important to many practitioners but are rarely used as metrics.
Antimicrobial use is a key driver of antimicrobial resistance, which is increasing and has detrimental effects on patients and healthcare systems [1] . This problem is compounded by the reduced number of antimicrobial agents approved in the past 25 years, with no clear recovery expected in the near future [2, 3] . The combination of increasing resistance and decreasing approvals of novel antibiotics highlights the need for antimicrobial stewardship.
Owing to increasing awareness of the need for judicious antimicrobial use, many institutions are implementing antimicrobial stewardship programs (ASPs) [4] . The Infectious Diseases Society of America/Society of Healthcare Epidemiology of America (IDSA/SHEA) guidelines promote ASPs to improve patient outcomes, not only through limiting inappropriate use, but also through optimizing antimicrobial selection while mitigating unintended consequences of antimicrobial use such as the emergence of resistance and adverse drug events; cost reduction is a secondary benefit [5] . However, no consensus exists regarding the optimal outcomes and metrics to show the impact of these programs.
METHODS
The IDSA/SHEA antimicrobial stewardship guidelines provide recommendations for developing an ASP with the goal of improving quality of care and outcomes. Approximately 5 years after the guidelines were published, we conducted a survey to identify outcomes opined by clinicians to be most important compared with those used in practice as ASP metrics. In March 2012, a 55question online survey was e-mailed to 94 physicians or pharmacists in acute care hospitals in the United States, with a 2-week collection period and 1 reminder e-mail. The distribution list was developed based on those institutions that had contact with the Medical Affairs department at Cubist Pharmaceuticals and were known to have existing ASPs or thought to be developing ASPs. Consent was obtained to use the survey data for research purposes.
Respondents had the option of submitting their responses directly via SurveyMonkey (Palo Alto, California) or an Adobe Acrobat (Adobe Systems, San Jose, California) file. The survey distribution list included only 1 respondent per institution. Survey responses were assessed for duplicates, and the consolidated data set was quality checked. Survey responses with identical IP (Internet protocol) addresses were combined, with the most recent survey taking precedent for questions with different answers. Two study team members each randomly compared 10% of the data in the final data set from 10% of the respondents to the source data ( portable document format [PDF] or electronic survey submissions) to ensure data accuracy after the collation process.
For purposes of the survey, an ASP was defined as having at least 1 person who performs and documents antimicrobial stewardship-related activities/interventions and contributes to the development of such policies/procedures as part of his/her job responsibilities. The outcomes or metrics available in the survey for selection by respondents were based on the IDSA/SHEA ASP guidelines and included antimicrobial use; antimicrobial cost; appropriateness of antimicrobial use; infection-related mortality rate; in-hospital mortality rate; antibiotic-associated length of stay; total length of stay; readmission; adherence to institutionspecific clinical guidelines/pathways; methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and Clostridium difficile infection rates; and hospital-acquired infection rates.
Descriptive statistics were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina) and Microsoft Excel 2007 (Microsoft Corporation, Redmond, Washington). Statistical significance was defined as a P value ≤.05 based on either χ 2 or Fisher exact test, as appropriate.
RESULTS
Respondents were from 48 institutions (51% response rate) in 29 states; 41 institutions reported having an active ASP (Tables 1 and 2 ). Of those with a program, respondents' opinion of which outcomes were important compared with those collected as metrics were antimicrobial use (15% vs 73%), antimicrobial cost (10% vs 73%), appropriateness of antimicrobial use (56% vs 51%), infection-related mortality rate (34% vs 7%), and antibiotic-associated length of stay (22% vs 12%) ( Table 3) . A divergence existed in respondent perception of the ASP outcomes that are most important to infectious disease (ID) physicians compared with hospital administrators, pharmacy directors, and pharmacy and therapeutics (P&T) committees. Infection-related mortality rate was perceived as the most important outcome for ID physicians, whereas antibiotic cost or use was thought to be the most important outcome for the other groups. When stratified according to presence or absence of an ID physician and pharmacist, electronic medical record (EMR) system, clinical decision support system (CDSS), or academic vs nonacademic center, antimicrobial use and cost remained the most commonly collected metrics, despite appropriateness of antimicrobial use, infection-related mortality rate, and antibiotic-associated length of stay being considered more important outcomes. The presence of an ID physician and pharmacist, compared with those programs without, increased the perceived importance (69% vs 27%, P = .03) and collection (62% vs 27%, P = .049) of appropriateness of antimicrobial use. Presence of an EMR or CDSS did not seem to enhance the collection of patient-centric outcomes.
DISCUSSION
The IDSA/SHEA guidelines provide recommendations for developing an ASP with the goal of improving quality of care and outcomes. Unfortunately, 5 years after publication of the guidelines, patient outcomes were still not widely assessed in this group of ASPs. Although <20% of respondents considered antimicrobial cost and use to be among the top 2 most important ASP outcomes, antimicrobial cost and use were the most common metrics evaluated among this group of programs. This general pattern remained when results were stratified according to presence or absence of an ID physician and pharmacist, EMR system, CDSS, or academic vs nonacademic institution. The metrics commonly used by ASPs (antimicrobial cost and use) may be driven, in part, by the perception of program personnel that these outcomes are most important to hospital administrators, pharmacy directors, and P&T committees. Although we do not address which outcomes ASPs should collect, we refer the reader to Dodds Ashley et al (this supplement) for additional insight. The survey results should be viewed within the context of limitations. First, not all collected surveys were completed, which may have been a result of the voluntary nature of the survey. However, only 9 (19%) surveys were incomplete. Second, the survey was sent to a single provider at each institution to help prevent duplication of results and potential skewing of the data by multiple respondents within 1 institution. Last, the sample size was small but represented a broad range of institution/ASP characteristics (Table 1) and was representative of the overall survey sample (data not shown). In light of a potential requirement for ASPs [6] and to advance the programs, ASP personnel must increase focus on patient outcomes and unintended consequences of antimicrobial use. Infection or antibioticassociated length of stay 5 (12) 9 (22) 2 (4.9) 0 (0) 1 (2) 3 (7)
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